Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U01NS093334 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Mayo Clinic | OTHER |
| Banner Health | OTHER |
| Brigham and Women's Hospital | OTHER |
| NYU Langone Health |
Not provided
Not provided
Not provided
Not provided
This is a study to develop methods of diagnosing chronic traumatic encephalopathy (CTE) during life, as well as to examine possible risk factors for this neurodegenerative disease. One component of this study is the use of an investigational PET scan radio tracer to detect abnormal tau protein in the brain.
Chronic Traumatic Encephalopathy (CTE) is a neurodegenerative disease characterized by a distinct deposition of phosphorylated tau (p-tau) in neurons and astrocytes in a pattern that is unique from other tauopathies, including Alzheimer's disease (AD). Although the neuropathological features of CTE have become further clarified in recent years, the clinical presentation of CTE is still not well characterized. Diagnostic criteria have only recently been published and lack validation.
Neuroimaging and fluid biomarkers developed for the diagnosis of other neurodegenerative diseases have only been used in preliminary studies of individuals at high risk for CTE, namely athletes with histories of significant exposure to repetitive head impacts (RHI), such as former football players and boxers. There is thus an urgent need to develop accurate methods for detecting and diagnosing CTE during life so that effective interventions for prevention and treatment can be developed. Moreover, though a history of RHI is a necessary risk factor for CTE, it alone is not sufficient. There is a need to understand what specific aspects of RHI exposure places an individual at increased risk for CTE and to examine potential genetic polymorphisms that modify that risk.
To address these needs, the investigators are conducting a multidisciplinary, multicenter, longitudinal study of former NFL and varsity college football players (with and without symptoms), and a control group of asymptomatic same-age men without any history of RHI exposure, traumatic brain injury or military service. Subjects will be seen at 1 of 4 participating study sites in Boston; Las Vegas, ; New York; and Scottsdale/Phoenix . Subjects will undergo a baseline evaluation and a 3 year follow-up evaluation (currently former college players will not complete the follow-up evaluation). Each evaluation will be take place over a 3 day period and consist of the following procedures/tests: neurocognitive testing, determination of functional independence, neuropsychiatric examination (with measures of mood and behavior), neurological assessment (motor, headache, postural stability), neuroimaging (including structural, diffusion, functional, biochemical, and molecular imaging), lumbar punctures (for Cerebrospinal Fluid (CSF) biomarkers), blood draws (for blood biomarkers and DNA), and saliva samples (for biomarkers).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Former NFL Players | 120 former National Football League players with and without reported cognitive, mood and behavior symptoms will be enrolled in this study. | ||
| Former College Football Players | 60 former college football players with and without reported cognitive, mood and behavior symptoms will be enrolled in this study. | ||
| Control Group | 60 asymptomatic same-age men without any history of participation in contact sports, military service, or traumatic brain injury will be enrolled in this study. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Neuroimaging Positron Emission Tomography for Amyloid Biomarker | Subjects will undergo a Florbetapir Positron Emission Tomography (PET) scan. The Outcome Measurement for the Florbetapir PET Scan will be "elevated" or "not elevated" | One-Time |
| Fluid Biomarkers | The following Biospecimens will be collected from subjects: Saliva, blood and cerebral spinal fluid (CSF). CSF will be collected by a lumbar puncture (spinal tap) Fluid biomarkers will be analyzed for the in vivo detection of CTE. | 3 Years |
| Neuropsychiatric and Neurocognitive Tests | Composite scores (presented as z scores) based on factor analytic methodology in the following domains:
| 3 years |
| Neurological Evaluation | Subjects will undergo The Movement Disorder Society's Unified Parkinson's Disorders Rating Scale (MDS-UPDRS) Neurological Evaluation by a physician. This evaluation will be analyzed to characterize the clinical presentation of CTE. | 3 years |
| Magnetic Resonance Imagining Biomarkers | Subjects will undergo Diffuser Tension Imaging (dti) and Functional MRI scans, to assess structural brain volumetrics, fractional anisotropy, radial diffusivity, and changes in brain activity associated with blood flow. | 3 years |
| Neuroimaging Positron Emission Tomography for Tau Biomarker | Subjects will undergo an Investigational drug: AV1451 Positron Emission Tomography (PET) scan. The Outcome Measurement for AV1451 PET scan will be Standardized Uptake Value Ratio (SUVR) of Tau. |
Not provided
Not provided
Inclusion Criteria:
Former NFL Players:
Former Collegiate Football Players
Control Group
Former NFL and Varsity Collegiate Football Players Exclusion Criteria:
Control Group Exclusion:
Not provided
Not provided
Former National Football League Players, Former Varsity Level College Football Players, Healthy Controls
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Robert A Stern, PhD | Boston University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Boston University School of Medicine | Boston | Massachusetts | 02118 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38134231 | Derived | Su Y, Protas H, Luo J, Chen K, Alosco ML, Adler CH, Balcer LJ, Bernick C, Au R, Banks SJ, Barr WB, Coleman MJ, Dodick DW, Katz DI, Marek KL, McClean MD, McKee AC, Mez J, Daneshvar DH, Palmisano JN, Peskind ER, Turner RW 2nd, Wethe JV, Rabinovici G, Johnson K, Tripodis Y, Cummings JL, Shenton ME, Stern RA, Reiman EM; DIAGNOSE CTE Research Project Investigators. Flortaucipir tau PET findings from former professional and college American football players in the DIAGNOSE CTE research project. Alzheimers Dement. 2024 Mar;20(3):1827-1838. doi: 10.1002/alz.13602. Epub 2023 Dec 22. | |
| 37798671 |
| Label | URL |
|---|---|
| Study website | View source |
Not provided
De-identified data will be shared with FITBIR and other data sharing portals
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000070627 | Chronic Traumatic Encephalopathy |
| ID | Term |
|---|---|
| D000070642 | Brain Injuries, Traumatic |
| D001930 | Brain Injuries |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
| OTHER |
| The Cleveland Clinic | OTHER |
| National Institute of Neurological Disorders and Stroke (NINDS) | NIH |
Not provided
Not provided
Not provided
Biospecimen samples to be collected include: saliva, blood and cerebral spinal fluid (CSF)
| 3 years |
| Magnetic Resonance Spectroscopy Biomarkers | Subject will also undergo Magnetic Resonance Spectroscopy (MRS) to measure glutamate, glutamine and myoinosotol. | 3 years |
| Derived |
| Stern RA, Trujillo-Rodriguez D, Tripodis Y, Pulukuri SV, Alosco ML, Adler CH, Balcer LJ, Bernick C, Baucom Z, Marek KL, McClean MD, Johnson KA, McKee AC, Stein TD, Mez J, Palmisano JN, Cummings JL, Shenton ME, Reiman EM; DIAGNOSE CTE Research Project Investigators. Amyloid PET across the cognitive spectrum in former professional and college American football players: findings from the DIAGNOSE CTE Research Project. Alzheimers Res Ther. 2023 Oct 5;15(1):166. doi: 10.1186/s13195-023-01315-5. |
| 34384490 | Derived | Alosco ML, Mariani ML, Adler CH, Balcer LJ, Bernick C, Au R, Banks SJ, Barr WB, Bouix S, Cantu RC, Coleman MJ, Dodick DW, Farrer LA, Geda YE, Katz DI, Koerte IK, Kowall NW, Lin AP, Marcus DS, Marek KL, McClean MD, McKee AC, Mez J, Palmisano JN, Peskind ER, Tripodis Y, Turner RW 2nd, Wethe JV, Cummings JL, Reiman EM, Shenton ME, Stern RA; DIAGNOSE CTE Research Project Investigators. Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project. Alzheimers Res Ther. 2021 Aug 12;13(1):136. doi: 10.1186/s13195-021-00872-x. |
| D009422 | Nervous System Diseases |
| D020208 | Brain Injury, Chronic |
| D019636 | Neurodegenerative Diseases |
| D006259 | Craniocerebral Trauma |
| D020196 | Trauma, Nervous System |
| D001925 | Brain Damage, Chronic |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D014947 | Wounds and Injuries |